The Effects of JNJ-39393406 on Psychometric Performance and Residual Depressive
Status:
Completed
Trial end date:
2017-07-01
Target enrollment:
Participant gender:
Summary
To evaluate the effects of the nicotinic allosteric modulator JNJ-39393406 on psychometric
performance and residual depressive symptoms in patients who have been diagnosed with
unipolar and bipolar depression but currently DO NOT meet criteria for an episode of Major
Depression or Manic Episode.
Phase:
Phase 2
Details
Lead Sponsor:
CliniRx Tangent Research Tangent Data
Collaborator:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.